Biotech opportunities for foreign companies doing business in China may be short-lived as the country builds its domestic biosimilars industry, according to a report released Tuesday by Sen. Marco Rubio (R-Fla.).
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,